Yahoo
HKSE - Delayed Quote HKD

WuXi XDC Cayman Inc. (2268.HK)

70.450 -0.850 (-1.19%)
At close: 4:08:05 PM GMT+8
Chart Range Bar
Loading chart for 2268.HK
  • Previous Close 71.300
  • Open 71.500
  • Bid 70.400 x --
  • Ask 70.450 x --
  • Day's Range 68.200 - 72.600
  • 52 Week Range 43.500 - 85.600
  • Volume 3,107,934
  • Avg. Volume 7,621,652
  • Market Cap (intraday) 89.215B
  • Beta (5Y Monthly) -0.87
  • PE Ratio (TTM) 55.04
  • EPS (TTM) 1.280
  • Earnings Date Aug 24, 2026
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 93.34

WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. Additionally, the company engages in the research and development, manufacturing, and marketing of anti-tumor drugs. WuXi XDC Cayman Inc. has a strategic collaboration with Earendil Labs; and Akari Therapeutics. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.

wuxixdc.com

3,628

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Performance Overview

Trailing total returns as of 10/26/2026, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .

YTD Return

2268.HK
16.06%
HANG SENG INDEX (^HSI)
9.44%

1-Year Return

2268.HK
0.07%
HANG SENG INDEX (^HSI)
11.27%

3-Year Return

2268.HK
161.41%
HANG SENG INDEX (^HSI)
36.18%

5-Year Return

2268.HK
161.41%
HANG SENG INDEX (^HSI)
10.86%

Analyst Insights

View More

Analyst Price Targets

71.51
93.34 Average
70.450 Current
108.73 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
As of 10/23/2026
  • Market Cap

    90.29B

  • Enterprise Value

    84.19B

  • Trailing P/E

    52.77

  • Forward P/E

    29.85

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    11.86

  • Price/Book (mrq)

    6.80

  • Enterprise Value/Revenue

    10.32

  • Enterprise Value/EBITDA

    38.61

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    22.38%

  • Return on Assets (ttm)

    9.32%

  • Return on Equity (ttm)

    16.33%

  • Revenue (ttm)

    6.94B

  • Net Income Avi to Common (ttm)

    1.55B

  • Diluted EPS (ttm)

    1.280

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.72B

  • Total Debt/Equity (mrq)

    4.59%

  • Levered Free Cash Flow (ttm)

    959.34M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: